Vivaldi Capital Management LP Gilead Sciences, Inc. Transaction History

Vivaldi Capital Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $270,768 - $314,412	-3,743 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $21,983 - $28,157	351 Added 10.35%	3,743 $280,000
Q4 2019 Feb 11, 2020	SELL	$61.62 - $67.78 $44,181 - $48,598	-717 Reduced 17.45%	3,392 $220,000
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $46,257 - $51,060	740 Added 21.96%	4,109 $260,000
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $208,440 - $233,741	3,369 New	3,369 $228,000
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $171,086 - $223,254	-2,826 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $201,437 - $223,027	2,826 New	2,826 $218,000
Q2 2018 Aug 13, 2018	SELL	$64.88 - $75.68 $177,511 - $207,060	-2,736 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$72.84 - $88.8 $199,290 - $242,956	2,736 New	2,736 $206,000
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $334,903 - $393,128	-4,707 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $339,421 - $402,307	4,707	4,707 $381,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Vivaldi Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Vivaldi Capital Management LP with notifications on news.